Firm-Wide blog

Invokana and Invokamet Increase the Risk of Leg and Foot Amputations

By Burg Simpson
May 18, 2017
2 min read

On May 16, 2017, the U.S. Food and Drug Administration (FDA) confirmed that Janssen Pharmaceuticals’ diabetes medications Invokana and Invokamet cause an increased risk of leg and foot amputations.  Accordingly, the FDA will now require these drugs to carry a black-box warning concerning this serious risk of injury.

FDA Safety Announcement

Invokana and Invokamet have an active ingredient known as canagliflozin and belong to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors.  These prescription medicines are often used with diet and exercise to lower blood sugar in adults with type 2 diabetes.

Although Invokana and Invokamet hit the market in 2013 and 2014 respectively, they continue to be part of long term clinical trials.  The final results from two of these trials demonstrated that patients taking canagliflozin-containing prescriptions were approximately twice as likely to have leg and foot amputations as those treated with a placebo.  Reported amputations most frequently involved a toe and middle of the foot.  There were however also reports of amputations involving the leg, below and above the knee, as well as some patients who had multiple amputations, some involving both limbs.

If you or a loved one have had a toe or leg amputated because of Invokana or Invokamet contact one of the experienced medical device attorneys at Burg Simpson today. Our award-winning lawyers would be happy to discuss your potential claim. Call 1-800-713-9340 or fill out our contact form for a FREE no-obligation consultation today.

Free case evaluation form